Abstract 55P
Background
Epidermal Growth Factor Receptor (EGFR) represents one of the main molecular druggable targets in non-small-cell lung cancer (NSCLC). Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor currently recognised as the standard of care for first-line treatment of EGFR-positive patients with common mutations (L858R or ex19del). Next Generation Sequencing (NGS) is recommended for routine use to detect gene mutation in NSCLC; moreover, NGS can quantitate the proportion of mutant variant reads for each mutation, the variant allele frequency (VAF). EGFR-VAF determined by liquid biopsy is known to be a prognostic factor in NSCLC patients. The role of EGFR-VAF determined on histological specimen in patients receiving first-line osimertinib is unclear.
Methods
From February 2019 to April 2023 a cohort of 68 patients with diagnosis of advanced EGFR mutated NSCLC started first-line osimertinib at San Raffaele Hospital, in Milan (Italy). We excluded from our analysis patients with VAF value unavailable (n=20). VAF was determined by NGS in pre-treatment baseline tissue samples.
Results
48 NSCLC patients were included in our analysis. Median EGFR-VAF was 31%, mean 35.9%, first quartile 17%, third quartile 52%. Cut-off of 50% was established to distinguish patients in high-VAF group (hVAF) and low-VAF (lVAF). Applying Log Rank test progression-free survival (PFS) was significantly shorter in hVAF patients [HR 0,30 (95% CI 0.12-0.8, p = 0.01)] than in lVAF group. With the limits of a 14.9 months median follow up, overall survival was significantly shorter in patients with high VAF [HR 0.19 (95% CI 0.056-0.648, p = 0.003)]. No correlation with other features (age, sex, smoke status, metastatic sites, PD-L1 expression) was found in covariate analysis, except for the mutation site L858R or ex19del, the latter being more frequently associated with hVAF.
Conclusions
High EGFR VAF on tissue seems to be predictive of a reduced response to osimertinib in NSCLC. Our findings must be validated on a greater number of cases, and a longer follow up is needed to confirm the correlation with shorter overall survival.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
S.T. Riva.
Funding
Has not received any funding.
Disclosure
R. Ferrara: Financial Interests, Personal, Advisory Board, In April 2022: MSD; Financial Interests, Personal, Advisory Board: Beigene; Financial Interests, Institutional, Invited Speaker: MSD, Pfizer, AstraZeneca, Roche, Sanofi, Novartis, BMS, Ipsen, Daiichi Sankyo Company. S. Pilotto: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, AstraZeneca, MSD, Roche, Amgen, Novartis, Takeda, Sanofi; Financial Interests, Personal, Advisory Board: MSD, Amgen, AstraZeneca, Novartis, Eli Lilly, Sanofi; Financial Interests, Personal, Research Grant: Bristol Myers Squibb, AstraZeneca; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Roche, BMS. A. Bulotta: Financial Interests, Personal, Advisory Board: Roche, BMS, AstraZeneca; Financial Interests, Institutional, Invited Speaker: BMS, MSD, AstraZeneca, Eli Lilly. M. Reni: Financial Interests, Personal, Advisory Board: Celgene, Eli Lilly, Pfizer, Baxalta, Shire, Novocure, Novartis, Boston Biomedicals; Non-Financial Interests, Institutional, Principal Investigator: Celgene. M. Milella: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Pfizer, Merck-Serono, Novartis, Ipsen, Viatris; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Institutional, Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract